Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

PCSK9 and Lipoprotein(a)

The Plot Thickens

Peter P. Toth
Download PDF
https://doi.org/10.1161/CIRCRESAHA.116.309011
Circulation Research. 2016;119:3-6
Originally published June 23, 2016
Peter P. Toth
From the CGH Medical Center, Sterling, IL; and Cicccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Disclosures
    • Acknowledgments
    • Sources of Funding
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • Editorials
  • adipocytes
  • extracellular space
  • hepatocyte
  • kinetic
  • lipoprotein(a)

Proprotein convertase subtilisin kexin type 9 (PCSK9) has rapidly become a focus of intensive investigation worldwide because of its linkage to multiple clinically important facets of hepatic lipoprotein metabolism. To facilitate secretion and proper folding, the zymogen pro-PCSK9 must undergo autocatalytic cleavage. Once in the extracellular space, mature PCSK9 does not engage in proteolytic activity because its active site is blocked by a prosegment.1 PCSK9 modulates the expression of a variety of cell surface receptors regulating lipoprotein and lipid trafficking across the cell membrane. Initial studies that lead to the identification of PCSK92 correlated 2 novel gain-of-function mutations in this enzyme with the phenotype of autosomal dominant hypercholesterolemia (familial hypercholesterolemia).3 Subsequent to these discoveries, loss-of-function mutations in PCSK9 were found to correlate with low serum levels of low-density lipoprotein cholesterol (LDL-C) and reduced risk for future cardiovascular events.4 Given these findings, PCSK9 has become an important therapeutic target in the management of dyslipidemia, and 2 monoclonal antibodies directed against it have recently been approved for use in patients with elevated LDL-C.

Article, see p 29

Much recent work has focused on how PCSK9 regulates the expression of the LDL receptor (LDLR). Once secreted into the extracellular milieu, PCSK9 can bind to a complex composed of the LDLR and an LDL particle. This binding occurs between the catalytic surface of PCSK95 and the epidermal growth factor–like repeat A domain of LDLR.6 The resulting complex is incorporated into clathrin-coated endosomal vesicles. The role of PCSK9 is to then chaperone the LDLR complex into the lysosome for hydrolytic destruction via an endosomal pathway, thereby reducing the recycling of LDLR to the hepatocyte cell surface and reducing LDL particle clearance capacity. This model neatly explains why gain-of-function and loss-of-function mutations would be etiologic for elevations and reductions in serum levels of LDL-C, respectively. However, PCSK9 turns out not to be quite so unidimensional.

PCSK9 regulates the expression of a variety of other cell surface receptors. PCSK9 regulates the expression of the LDLR-related protein-1,7 the very-low-density lipoprotein receptor, and the apolipoprotein E receptor 2.8 In addition, PCSK9 has been shown to downregulate the expression of cluster of differentiation 36 (CD36), a transmembrane protein that functions as a fatty acid translocase in hepatocytes and adipocytes.9 PCSK9 increases lysosomal degradation of CD36 via a proteasome-dependent pathway. It is not yet established whether PCSK9 impacts LDL scavenging via CD36 by macrophage-derived foam cells. However, the decreased expression of these various non-LDLRs could potentially impact systemic clearance of remnant lipoproteins and fatty acids. Of great interest is the recent observation that a physical interaction between intracellular PCSK9 and apoprotein B (apoB) decreases the catabolism of apoB via an autophagosome/lysosome pathway and results in increased secretion of apoB lipoproteins.10 Overproduction or impaired catabolism of PCSK9 would thus be expected to exacerbate dyslipidemia by potentiating hepatic production and secretion of apoB-containing lipoproteins.

Are there any naturally occurring inhibitors or modulators of PCSK9 activity? It seems there are, although clearly the picture remains incomplete. Annexin A2 induces a conformational change in PCSK9, thereby reducing the functional activity of this enzyme and inducing increased expression of LDLR.11 In addition to binding to LDLR, PCSK9 can bind to LDL particles in plasma.12 It is estimated that 1 in 500 to 1000 LDL particles in plasma forms a complex with PCSK9.13 This sequestering of PCSK9 by LDL complex formation would result in indirect inhibition because less PCSK9 would be available along the hepatocyte cell surface to bind LDLR. Kosenko et al14 demonstrated that ≈40% of the total PCSK9 in circulation is bound to LDL particles. The binding of PCSK9 occurs via its N terminus, and kinetic studies are consistent with a single binding site on LDL. Hence, it is possible that LDL particles regulate their uptake by limiting serum levels of PCSK9. It remains to be determined if a specific subpopulation of LDLs with a proteome variant binds PCSK9 or if it is a random event with a fixed binding site. It is also of interest to establish whether some patients bare particular efficiency for PCSK9 sequestration by LDL particles. Furin is a serine protease that cleaves PCSK9 at Arg218, thereby converting its 62-kDa active form into a 55-kDa inactive one.15 The role of furin in PCSK9 regulation in vivo is not yet defined.

For >5 decades, it has not been clear how lipoprotein(a) (Lp(a)) is removed from the circulation. Rader et al16 demonstrated that Lp(a) clearance rates were identical between patients with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, and normal controls, suggesting that Lp(a) uptake occurs via a pathway that is independent of LDLR. Lp(a) is highly atherogenic, and its serum levels are genetically determined. Similar to other LDLs, it is found in atherosclerotic plaque. It may confer increased risk for thrombosis secondary to apolipoprotein(a) which has significant sequence homology to plasminogen. It has also been identified as an important carrier vehicle and delivery platform for oxidized phospholipids, which can boost intravascular inflammation and potentiate atherogenesis. Multiple prospective observational cohorts confirm that Lp(a) correlates highly with risk for myocardial infarction, ischemic stroke, aortic valve calcification, peripheral atrial disease, and mortality.17–19 Statin therapy has not been shown to attenuate the excess risk for cardiovascular morbidity or mortality attributable to elevations in Lp(a).20 Lipoprotein apheresis is an effective method for clearing Lp(a). Multiple types of molecular interventions for lowering Lp(a) are in development.

It is known that monoclonal antibodies directed against PCSK9 reduce serum levels of Lp(a) significantly.21,22 Recent investigation suggests that the PCSK9 monoclonal antibodies decrease Lp(a) via LDLR according to the following: (1) there are greater numbers of LDLRs to bind and clear Lp(a) particles and (2) by inducing dramatic reductions in LDL particles, there are more binding sites available with less kinetic competition for Lp(a) to bind to these sites.23 Romagnuolo et al24 demonstrated that overexpression of LDLR in HepG2 cells facilitates Lp(a) uptake via the LDL portion of Lp(a) and not its apolipoprotein(a) moiety. Moreover, similar to that for LDL, Lp(a) uptake was dependent on clathrin-coated pits and a lysosome-dependent pathway. It is not yet known whether PCSK9 antagonism specifically reduces the production and secretion of Lp(a) or whether it facilitates Lp(a) clearance via lipoprotein cell surface receptors other than LDLR.

Is there more to the story? There has to be. In this issue of Circulation Research, Tavori et al25 hypothesized that because Lp(a) is a variant of LDL, it too binds and sequesters some amount of PCSK9 in serum. Interestingly, it does. In a cohort comprised dyslipidemic patients with Lp(a) mass concentrations of 39 to 320 mg/dL, these investigators convincingly demonstrated using ultracentrifugation, immunoprecipitation, and an ELISA that Lp(a) binds PCSK9 in serum. PCSK9 binds to apoB, and the binding is independent of the number of kringle IV-2 repeats or whether or not the Lp(a) contains the apolipoprotein(a) region that binds oxidized phospholipid, and there is a direct relationship between Lp(a)-associated PCSK9 and plasma Lp(a) levels. The PCSK9 associated with Lp(a) is intact and not hydrolyzed by furin. Fully one quarter of PCSK9 in plasma is associated with Lp(a) in these patients with elevations in this lipoprotein. At least in patients with elevated Lp(a), PCSK9 seems to have some preferential binding (1.7-fold higher) for Lp(a) compared with LDL. However, with only 1 out of 175 Lp(a) particles binding PCSK9, this represents a very small percentage of total Lp(a) that is complexed. In patients with lower plasma levels of Lp(a), this percentage would be expected to be still lower. Does this represent passive, random association? Is it a means of sequestering PCSK9 and rendering it incapable of binding to LDLR, or does it constitute a tagging of sorts to mark a small subpopulation of Lp(a) particles for a different metabolic fate? We do not know yet.

The functional significance of the association between PCSK9 and Lp(a) cannot be gleaned from these data. The PCSK9 monoclonal antibodies are approved for clinical use in the United States and Europe. To date, they have demonstrated an acceptable level of safety and reduce atherogenic lipoprotein burden in serum to a remarkable degree. The results of cardiovascular outcome trials with these agents are eagerly awaited. Clearly, our knowledge, although advancing rapidly, is rudimentary, and there is much about the molecular dynamics of PCSK9 that we still do not know. Given the growing, important role these agents are expected to play in the management of patients with dyslipidemia, it is imperative that further investigation continues to more fully sort out the comprehensive range of PCSK9’s activity in all tissues (especially the liver and intestine) in which it is expressed, how its antagonism impacts lipoprotein trafficking in plasma and lipid/lipoprotein metabolism in specific cell types, and how different tissues may engage in molecular cross talk secondary to increases or decreases in PCSK9 functionality. You can expect the results to be both fascinating and marvelously surprising.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Proprotein convertase subtilisin kexin type 9 (PCSK9) and lipoprotein trafficking. Subsequent to release from the Golgi apparatus, low-density lipoprotein receptors (LDLR) translocate to the cell membrane where they are concentrated in clathrin-coated pits. Hepatocytes secrete PCSK9 into the extracellular space which can bind to the epidermal growth factor–like repeat A (EGF-A) domain of LDLR. Complexes composed of LDLR and LDL particles are internalized via endosomes. If the LDLR–LDL-P complex is bound with PCSK9, the complex is chaperoned into the lysosome for hydrolytic destruction. The LDLR in this case is not recycled to the cell surface. When LDLR–LDL-P complexes are not bound to PCSK9, the complex dissociates in response to a drop in pH within the endosome. The LDL-P is translocated to the lysosome for destruction, whereas LDLR is spared and recycled to the cell surface to initiate another round of LDL-P binding and uptake. The monoclonal antibodies directed against PCSK9 decrease LDLR translocation into the lysosome, increase LDLR surface expression, and significantly reduce plasma levels of LDL-P. Recent investigations demonstrate that PCSK9 can also regulate the expression of other cell surface receptors, such as a very-low-density lipoprotein receptor (VLDLR), the LDLR-related protein (LRP), an apoprotein E receptor, and cluster of differentiation 36 (CD36). In addition to its impact on cell surface receptor expression, PCSK9 potentiates the production of apo B and increases VLDL secretion by inhibiting the catabolism of apoB via an autophagosome/lysosome-dependent pathway. The serine protease furin (which is found in both membrane-bound and free forms) can cleave active, intact PCSK9 (62 kDa) into an inactive 55-kDa fragment. A small percentage of total circulating LDL and lipoprotein(a) (Lp(a)) can bind PCSK9. Although some Lp(a) is cleared by a pathway that is independent of LDLR, some is demonstrably cleared by LDLR.

Disclosures

Dr Toth is a member of the speaker’s bureau for Amgen, Amarin, Kowa, Merck, Regeneron-Sanofi and consultant to Amgen, Amarin, AstraZeneca, Kowa, Merck, and Regeneron-Sanofi.

Acknowledgments

I gratefully acknowledges Dr Thomas Dayspring who provided the figure contained herein.

Sources of Funding

None.

Footnotes

  • The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

  • © 2016 American Heart Association, Inc.

References

  1. 1.↵
    1. Cunningham D,
    2. Danley DE,
    3. Geoghegan KF,
    4. et al
    . Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14:413–419. doi: 10.1038/nsmb1235.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Seidah NG,
    2. Benjannet S,
    3. Wickham L,
    4. Marcinkiewicz J,
    5. Jasmin SB,
    6. Stifani S,
    7. Basak A,
    8. Prat A,
    9. Chretien M
    . The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100:928–933. doi: 10.1073/pnas.0335507100.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Abifadel M,
    2. Varret M,
    3. Rabès JP,
    4. et al
    . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156. doi: 10.1038/ng1161.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Cohen JC,
    2. Boerwinkle E,
    3. Mosley TH Jr.,
    4. Hobbs HH
    . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272. doi: 10.1056/NEJMoa054013.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kwon HJ,
    2. Lagace TA,
    3. McNutt MC,
    4. Horton JD,
    5. Deisenhofer J
    . Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA. 2008;105:1820–1825. doi: 10.1073/pnas.0712064105.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Zhang DW,
    2. Lagace TA,
    3. Garuti R,
    4. Zhao Z,
    5. McDonald M,
    6. Horton JD,
    7. Cohen JC,
    8. Hobbs HH
    . Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602–18612. doi: 10.1074/jbc.M702027200.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Canuel M,
    2. Sun X,
    3. Asselin MC,
    4. Paramithiotis E,
    5. Prat A,
    6. Seidah NG
    . Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One. 2013;8:e64145. doi: 10.1371/journal.pone.0064145.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Poirier S,
    2. Mayer G,
    3. Benjannet S,
    4. Bergeron E,
    5. Marcinkiewicz J,
    6. Nassoury N,
    7. Mayer H,
    8. Nimpf J,
    9. Prat A,
    10. Seidah NG
    . The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363–2372. doi: 10.1074/jbc.M708098200.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Demers A,
    2. Samami S,
    3. Lauzier B,
    4. Des Rosiers C,
    5. Sock ET,
    6. Ong H,
    7. Mayer G
    . PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015;35:2517–2525. doi: 10.1161/ATVBAHA.115.306032.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Sun H,
    2. Samarghandi A,
    3. Zhang N,
    4. Yao Z,
    5. Xiong M,
    6. Teng BB
    . Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012;32:1585–1595. doi: 10.1161/ATVBAHA.112.250043.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Seidah NG,
    2. Prat A
    . The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–383.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Fan D,
    2. Yancey PG,
    3. Qiu S,
    4. Ding L,
    5. Weeber EJ,
    6. Linton MF,
    7. Fazio S
    . Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008;47:1631–1639. doi: 10.1021/bi7016359.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Tavori H,
    2. Giunzioni I,
    3. Linton MF,
    4. Fazio S
    . Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res. 2013;113:1290–1295. doi: 10.1161/CIRCRESAHA.113.302655.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Kosenko T,
    2. Golder M,
    3. Leblond G,
    4. Weng W,
    5. Lagace TA
    . Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem. 2013;288:8279–8288. doi: 10.1074/jbc.M112.421370.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Essalmani R,
    2. Susan-Resiga D,
    3. Chamberland A,
    4. Abifadel M,
    5. Creemers JW,
    6. Boileau C,
    7. Seidah NG,
    8. Prat A
    . In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem. 2011;286:4257–4263. doi: 10.1074/jbc.M110.192104.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Rader DJ,
    2. Mann WA,
    3. Cain W,
    4. Kraft HG,
    5. Usher D,
    6. Zech LA,
    7. Hoeg JM,
    8. Davignon J,
    9. Lupien P,
    10. Grossman M
    . The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403–1408. doi: 10.1172/JCI117794.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bouchareb R,
    2. Mahmut A,
    3. Nsaibia MJ,
    4. et al
    . Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 2015;132:677–690. doi: 10.1161/CIRCULATIONAHA.115.016757.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Gurdasani D,
    2. Sjouke B,
    3. Tsimikas S,
    4. Hovingh GK,
    5. Luben RN,
    6. Wainwright NW,
    7. Pomilla C,
    8. Wareham NJ,
    9. Khaw KT,
    10. Boekholdt SM,
    11. Sandhu MS
    . Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058–3065. doi: 10.1161/ATVBAHA.112.255521.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Kamstrup PR,
    2. Benn M,
    3. Tybjaerg-Hansen A,
    4. Nordestgaard BG
    . Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117:176–184. doi: 10.1161/CIRCULATIONAHA.107.715698.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Khera AV,
    2. Everett BM,
    3. Caulfield MP,
    4. Hantash FM,
    5. Wohlgemuth J,
    6. Ridker PM,
    7. Mora S
    . Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635–642. doi: 10.1161/CIRCULATIONAHA.113.004406.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Desai NR,
    2. Kohli P,
    3. Giugliano RP,
    4. O’Donoghue ML,
    5. Somaratne R,
    6. Zhou J,
    7. Hoffman EB,
    8. Huang F,
    9. Rogers WJ,
    10. Wasserman SM,
    11. Scott R,
    12. Sabatine MS
    . AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013;128:962–969. doi: 10.1161/CIRCULATIONAHA.113.001969.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Gaudet D,
    2. Kereiakes DJ,
    3. McKenney JM,
    4. Roth EM,
    5. Hanotin C,
    6. Gipe D,
    7. Du Y,
    8. Ferrand AC,
    9. Ginsberg HN,
    10. Stein EA
    . Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114:711–715. doi: 10.1016/j.amjcard.2014.05.060.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Raal FJ,
    2. Giugliano RP,
    3. Sabatine MS,
    4. Koren MJ,
    5. Blom D,
    6. Seidah NG,
    7. Honarpour N,
    8. Lira A,
    9. Xue A,
    10. Chirovolu P,
    11. Jackson S,
    12. Di M,
    13. Peach M,
    14. Somaratne R,
    15. Wasserman SM,
    16. Scott R,
    17. Stein EA
    . PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the role of the LDL receptor. J Lipid Res. 2016.
  24. 24.↵
    1. Romagnuolo R,
    2. Scipione CA,
    3. Boffa MB,
    4. Marcovina SM,
    5. Seidah NG,
    6. Koschinsky ML
    . Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290:11649–11662. doi: 10.1074/jbc.M114.611988.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Tavori H,
    2. Christian D,
    3. Minnier J,
    4. Plubell D,
    5. Shapiro MD,
    6. Yeang C,
    7. Giunzioni I,
    8. Croyal M,
    9. Duell PB,
    10. Lambert G,
    11. Tsimikas S,
    12. Fazio S
    . PCSK9 association with lipoprotein(a). Circ Res. 2016;119:29–35. doi: 10.1161/CIRCRESAHA.116.308811.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
June 24, 2016, Volume 119, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Disclosures
    • Acknowledgments
    • Sources of Funding
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    PCSK9 and Lipoprotein(a)
    Peter P. Toth
    Circulation Research. 2016;119:3-6, originally published June 23, 2016
    https://doi.org/10.1161/CIRCRESAHA.116.309011

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    PCSK9 and Lipoprotein(a)
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    PCSK9 and Lipoprotein(a)
    Peter P. Toth
    Circulation Research. 2016;119:3-6, originally published June 23, 2016
    https://doi.org/10.1161/CIRCRESAHA.116.309011
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Mechanisms
    • Vascular Biology
    • Lipids and Cholesterol
    • Basic Science Research

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured